Loteprednol Etabonate Suspension/ Drops
NDC Package 70244-034-01
Package Information
Loteprednol Etabonate suspension/ dropses is a medication used to treat certain eye conditions due to inflammation or injury. This formulation utilizes a suspension/ drops delivery system. Marketed by Sentiss Pharmaceuticals Llc, this product is identified by NDC 70244-034 and is authorized under FDA application ANDA207609.
Identification & Billing
- RxCUI: 311382 - loteprednol etabonate 0.5 % Ophthalmic Suspension
- RxCUI: 311382 - loteprednol etabonate 5 MG/ML Ophthalmic Suspension
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 70244 - Sentiss Pharmaceuticals Llc
- 70244-034 - Loteprednol Etabonate
- 70244-034-01 - 1 BOTTLE, DROPPER in 1 CARTON / 5 mL in 1 BOTTLE, DROPPER
- 70244-034 - Loteprednol Etabonate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (70244-034). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 70244-034-01 identifies a specific commercial package of 1 bottle, dropper in 1 carton / 5 ml in 1 bottle, dropper of Loteprednol Etabonate, a human prescription drug labeled by Sentiss Pharmaceuticals Llc. This suspension/ drops is formulated for ophthalmic use and contains loteprednol etabonate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Sentiss Pharmaceuticals Llc on April 17, 2026. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
This medication is used to treat certain eye conditions due to inflammation or injury. It is also used after eye surgery. Loteprednol works by relieving symptoms such as swelling, redness, and itching. It belongs to a class of drugs known as corticosteroids.
How is this Sentiss Pharmaceuticals Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 70244003401. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.